Transcriptomic response of breast cancer cells to anacardic acid

Abstract

Anacardic acid (AnAc), a potential dietary agent for preventing and treating breast cancer, inhibited the proliferation of estrogen receptor α (ERα) positive MCF-7 and MDA-MB-231 triple negative breast cancer cells. To characterize potential regulators of AnAc action, MCF-7 and MDA-MB-231 cells were treated for 6 h with purified AnAc 24:1n5 congener followed by next generation transcriptomic sequencing (RNA-seq) and network analysis. We reported that AnAc-differentially regulated miRNA transcriptomes in each cell line and now identify AnAc-regulated changes in mRNA and lncRNA transcript expression. In MCF-7 cells, 80 AnAc-responsive genes were identified, including lncRNA MIR22HG. More AnAc-responsive genes (886) were identified in MDA-MB-231 cells. Only six genes were commonly altered by AnAc in both cell lines: SCD, INSIG1, and TGM2 were decreased and PDK4, GPR176, and ZBT20 were increased. Modeling of AnAc-induced gene changes suggests that AnAc inhibits monounsaturated fatty acid biosynthesis in both cell lines and increases endoplasmic reticulum stress in MDA-MB-231 cells. Since modeling of downregulated genes implicated NFκB in MCF-7, we confirmed that AnAc inhibited TNFα-induced NFκB reporter activity in MCF-7 cells. These data identify new targets and pathways that may account for AnAc’s anti-proliferative and pro-apoptotic activity.

RETRACTED ARTICLE: LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p

“…**P < 0.01, compared with miR-NC group, si-NC group or normal tissue group in several kinds of cancers. For example, Li et al found that SNHG7 promoted colorectal cancer progression by acting as a ceRNA of miR-34a and thereby increasing GALN7 expression level [10]. SNHG7 could also accelerate prostate cancer proliferation via miR-503/Cyclin D1 pathway [11].…”

“…For example, HOT-TIP, MALAT1 and MEG3 are regarded as important regulators of tumor progression [7]. Small nucleolar RNA host gene 7 (SNHG7), a lncRNA located on chromosome 9q34.3 with a length of 2157 bp, is a novel identified oncogenic gene functioning in different types of human cancers, including breast cancer, bladder cancer, colorectal cancer and prostate cancer [8][9][10][11]. However, little is known about the role of SNHG7 in PC.…”

DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood

“…These studies identified between 0 and 2761 differentially methylated CpGs, with none of the identified differentially methylated sites overlapping between these studies, and suffered major methodological issues, especially pertaining to incomplete control of confounding and suboptimal preprocessing methods [4]. Nevertheless, four of our detected differentially methylated CpGs in the main analysis were also differentially methylated in the same direction of association (all hypomethylated in breast cancer) in previous epigenome-wide studies, namely cg07180460 (ZSWIM6), cg22731164 (GPR176), and cg18726036 (FKBP5) in a study of blood DNA methylation from the Sister Study [37], and cg02168584 (DLX2-AS1) in a study of genetically predicted DNA methylation of patients from the Breast Cancer Association Consortium [38], all of which have been shown to be dysregulated in breast cancer cell lines [39][40][41][42].…”

Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer

“…Besides, its increased expression seems to be stimulated by cell-free DNA from colorectal cancer cells [54], and by treating cell lines with chemotherapy agents. Increased expression of the INSIG1 gene was described in breast cancer cell lines after treatment with gemcitabine and 5-FU [55], while decreased expression was detected after treating a laryngeal cancer cell line with low doses of paclitaxel [56], and after anacardic acid treatment in breast cancer cell lines [57].…”